Please login to the form below

basal cell carcinoma

This page shows the latest basal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Sanofi/Regeneron’s IO latecomer Libtayo approved in Europe

cell carcinoma and cervical cancer. ... Sanofi and Regeneron aren’t holding back on the scale of their research programme, and these include trials in squamous cell carcinoma of the head and neck, melanoma, colorectal cancer, prostate

Latest news

Pfizer gets first FDA nod for hedgehog inhibitor in AML

The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... metastatic non-small cell lung cancer (NSCLC),
Sanofi’s latecomer PD-1 gets date for FDA verdict

The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... after basal cell carcinoma (BCC) and the deadliest
Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The data in cutaneous squamous cell carcinoma (CSCC), the second most common form of skin cancer, comes from a single-arm, open-label trial involving 82 patients and showed an overall ... The company plans to have pivotal trials ongoing in first-line
Pfizer's SMO inhibitor boosts survival in blood cancer trial

basal cell carcinoma in patients not suitable for surgery or radiotherapy. ... in a phase I/II trial in small cell lung cancer (SCLC) patients.
Rare disease therapies head the ‘class of 2015’

A product in a new class of cancer therapies that harness the cell-killing power of viruses also debuted in 2015 in the form of Amgen's Imlygic (talimogene laherparepvec), the ... Actelion. USA. sonidegib. Odomzo. basal cell carcinoma. SMO receptor

More from news
Approximately 5 fully matching, plus 13 partially matching documents found.

Latest Intelligence

Drug launches to watch in 2019

1. Zolgensma – the $4m per patient gene therapy. The first CAR-T cell therapies, Novartis’ Kymriah and Gilead/Kite’s Yescarta, were launched in Europe in 2018, while Spark’s gene ... The small-molecule drug blocks part of the Sonic hedgehog
Deal Watch December 2016

295. Novartis (Switzerland). Sun Pharma (India). Asset acquisition. Odomzo (sonidegib; hedgehog pathway inhibitor), approved in basal cell carcinoma. ... Abzena's technology is used to humanise and de-immunise antibodies by avoiding CD4+ T-cell epitopes.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

Chris Bowden joins Agios

During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.
Curis looks to MedImmune and Takeda for new hires

Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Associate Medical Writer / Entry Level Medical Writer - Medical ...: DOE

Scientific Director - Medical Education - Cheshire & London ...: Excellent Remuneration Package

Account Director, Medical Education: Salary TBC

Senior Medical Writer: Salary TBC

Graduate / Entry Level Opportunities – Medical Communications – ...: Highly Competitive Remuneration Package

Senior Medical Writer– Medical Education – Oxford - London: Excellent Remuneration Package

Account Director – Cheshire based Medical Communications Agency...: D.O.E

Senior / Principal Medical Writer – Medical Education - UK &...: Excellent Salary and Benefits on offer

Scientific Director - Medical Communications Agency - New York: Excellent Remuneration Package

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Senior Medical Writer – Leading Medical Communications Agency – ...: Highly Competitive Remuneration Package

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Experienced / Senior Medical Writer - MedComms - Cardiff - Wales: Excellent Salary and Benefits on offer

Subscribe to our email news alerts

PMHub

Add my company

An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

Five key trends in precision and personalised healthcare: Here, we deep dive into five of the key trends in precision medicine and personalised healthcare to explore how the healthcare industry is changing and how pharmaceutical and biotech companies...
OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications: Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word: ...